GLP-1 Deep Dive — Bundle into longevity, own the male share

Comprehensive sourced analysis of GLP-1 medications (Mounjaro, Wegovy, Ozempic, Saxenda, Rybelsus) as a defensible service line for DoctoriumGP — covering the UK private market, wholesale economics, regulatory pathway, patient demographics, corporate B2B opportunity, ROI scenarios, and a recommended positioning.

Date compiled: 25 April 2026. UK English throughout. Inferences and modelled numbers explicitly flagged.

---

Executive Summary (TL;DR)

1. The UK private GLP-1 market is enormous and still growing. ~500,000 patients are paying privately, ~1.6 million UK adults used a weight-loss drug in the past 12 months, and the UK prescription weight-loss medications market is projected at USD 421m (2025) → USD 2.49bn (2033) at 24.85% CAGR. Private channel = 66.7% of value. (Grand View Research, Lyv launch GlobeNewswire, DDW)
2. Pricing has reset upward. Eli Lilly's 1 Sept 2025 price increase pushed wholesale Mounjaro from £92–£122 to £133–£330 per pen (up to 170%). NHS Drug Tariff was redetermined at the new prices. (NHSBSA, Pharma Exec)
3. Retail spread is now £140–£375/month. Cheapest UK providers (Live Well, Medino, Pharmacy Online) sell 2.5 mg at £133–£149. Premium operators (Numan, Boots, Lloyds, Voy 1-month plan) sit at £190–£215 for 2.5 mg. Top of ladder (15 mg) ranges £287 (Medino) → £370 (Superdrug). (Live Well, Medino)
4. The default UK GLP-1 patient is female (78%), aged 30–49, BMI ≥ 35, in less-deprived postcodes. This is a market gap — male share is ~22%. DoctoriumGP can win by aggressively pricing the male executive segment, where there is no dominant brand. (Health Foundation/Voy)
5. Recommended positioning: GLP-1 should be the acquisition wedge into the men's longevity bundle, not a standalone product. Sold standalone the gross margin is thin (£40–£90/month per patient at competitive prices) but bundled with bloods (Stride/GlycanAge), Tanita, quarterly review, and a longevity portal it underwrites a £300–£500 ARPU subscription with strong retention.
6. Corporate B2B is the highest-leverage segment because (a) employers see £4,340–£7,165 in productivity loss per overweight/obese employee per year (Frontier Economics 2025), (b) only Vitality currently bundles a GLP-1 discount, so DGP can sell direct to mid-size employers (50–500 staff) without competing with PMI, and (c) ASA rules effectively shut off direct B2C GLP-1 advertising — B2B sidesteps the problem entirely.
7. Conservative 12-month scenario (DGP solo): 80 active patients @ £225 ARPU × 12 = £216k revenue, ~£72k gross contribution after COGS + clinical time. 36-month base case: 350 active patients × £240 ARPU = £1.0m+ recurring revenue line with cross-sell into longevity bundle and corporate.

---

A. UK Private GLP-1 Market — Operator-by-Operator Pricing Scan

A.1 The 2025 wholesale reset

On 14 August 2025 Eli Lilly announced a UK list price increase of up to 170% for Mounjaro, effective 1 September 2025. The 15 mg dose moved from £122 → £330 per pen (per pen = 4 weekly doses = ~one month). The 2.5 mg starter rose from £92 → £133. (PharmExec, Euronews)

The NHS Drug Tariff was redetermined to match (Sept 2025 prescriptions reimbursed at the new list, with the Drug Tariff catching up in Oct 2025). (NHSBSA, Community Pharmacy England)

Critical wrinkle: the Eli Lilly rebate. Lilly invited pharmacies to sign a commercial supply agreement that returns a (publicly undisclosed) per-pen rebate. This is the single biggest reason retail prices vary by >£100/month for the same pen. Pharmacies that sign the rebate deal can sell at £133–£170 for 2.5 mg; those that don't are pinned near £200+. (Community Pharmacy England — Mounjaro pricing for pharmacy owners, Pharmaceutical Journal) Action for DGP: sign the Lilly commercial agreement before quoting retail prices.

A.2 UK provider price ladder — Mounjaro (1-month supply, March/April 2026)

Sources: Live Well 2026 comparison, Medino, Numan, Boots Online Doctor, Voy, Juniper UK, MyBMI, Asda, Lloyds Pharmacy Online Doctor, Superdrug Online Doctor.

Key observations: - The 2.5 mg starter dose is a loss-leader at most online pharmacies — gross margin of £0–£20 at the cheapest providers given £133 list. They earn back on 7.5–15 mg maintenance. - Numan, Voy, Juniper are charging a clear "service premium" of £40–£90/month over the bare-pharmacy price for coaching/app/clinician access. This is the bundle DGP should compete with. - Vitality + Boots discount scheme offers up to 20% off (≈£1,000/year saving on top dose) for active Vitality members (Vitality enhancements, My Health Protected).

A.3 Wegovy ladder (semaglutide, Novo Nordisk)

Sources: HeySlim Wegovy guide, MyBMI, Voy, Boots Online Doctor.

• Range: £79–£329/month privately depending on dose and provider
• Starter doses (0.25 mg & 0.5 mg): £79–£200
• Maintenance (1 mg / 1.7 mg / 2.4 mg): £135–£329
• New 7.2 mg dose (licensed Jan 2026): £278–£279/month at MyBMI, full launch pending
• MyBMI Wegovy starts £119/month; Boots £199–£229; Voy starts £169/month with £144–£239 ladder; Juniper cut Wegovy programme 25% post-Sept 2025 (now £189–£299)

Key shift: post-Sept 2025, Wegovy is now £50–£100/month cheaper than Mounjaro at equivalent dose stages — first time the rank has flipped. (Pharmacy2U comparison via Bolt)

A.4 Other GLP-1s

• Ozempic (semaglutide 0.5/1/2 mg) — not licensed for weight loss in UK but widely prescribed off-label privately. Typical retail £130–£200/month; Simple Online Pharmacy from £37.25 starter, MedsForLess £169.99. Off-label demand has eased as Wegovy supply normalised. (Joinvoy Ozempic page, Asda)
• Saxenda (liraglutide, daily injection) — increasingly legacy product; £49–£59 per pen at most online clinics, ~£250/month for full course. Largely displaced by once-weekly Mounjaro/Wegovy. (London Slimming Clinic, PrivateDoc)
• Rybelsus (oral semaglutide) — licensed for type 2 diabetes only. Off-label weight-loss prescribing happens but is regulatorily fragile (no MHRA marketing authorisation for higher 25/50 mg weight-loss doses as of April 2026). Private cost £150–£250/month (Mayfair £175 for 3 mg, £195 for 14 mg). (glp1treatments.co.uk, Mayfair Weight Loss Clinic)

Recommendation for DGP: lead with Mounjaro and Wegovy only. Saxenda is legacy. Ozempic and Rybelsus carry off-label risk that's unhelpful when building a clinical-quality longevity brand.

---

B. Wholesale / Clinic-Purchase Economics

B.1 What DoctoriumGP actually pays

Per the NHSBSA Drug Tariff redetermination and Eli Lilly's UK price increase notice, Mounjaro list prices from 1 September 2025:

(Mid-ladder prices inferred from public pharmacy commentary — exact intermediate doses not separately disclosed in NHSBSA notice but consistent with commercial reporting.)

Lilly rebate. The commercial supply agreement allows pharmacies to claim back a portion of the cost (value not publicly disclosed; estimated £20–£60 per pen based on observed price spread). Without the rebate, a clinic margin on 2.5 mg sold at £150 retail is £17 — roughly break-even after delivery and consumables. With the rebate, it's £40–£70.

B.2 Wegovy wholesale

Novo Nordisk does not publish UK wholesale numbers as transparently as Lilly's reset. Inferred from reverse-engineering retail (£79–£199 cheapest end, with a typical operator gross margin of 30–60% in the model below): - Starter doses (0.25/0.5 mg): inferred wholesale £55–£90 - Mid-ladder (1.0–1.7 mg): inferred £100–£160 - Top dose (2.4 mg): inferred £140–£200 - New 7.2 mg dose (Jan 2026 launch): inferred £180–£230

(All Wegovy figures are inferred from competitive retail; verify with Novo Nordisk UK distributor before committing pricing.)

B.3 Industry margin rule of thumb

Pharmacy commentary and The Care Pharmacy / Bolt Pharmacy commercial guides consistently describe markup of 30–100% over wholesale in the private weight-loss space, with bundled-service operators (Numan, Voy) at the top of that range and bare-pharmacy operators (Live Well, Medino) at the bottom.

For DGP a defensible target is 40–70% gross margin on the medicine itself, with the bundle (consult, blood tests, app, coaching) carrying the rest of the value. That puts retail at: - 2.5 mg at £190–£220 (vs Numan £209) — DGP sits in the premium-clinical band, not the cheap-pharmacy band - 15 mg at £350–£400

B.4 Cold-chain and dispensing model

Per Bolt Pharmacy storage guide and NovoNordisk Medical: - Pre-opened storage: 2–8°C (validated fridge) - Post-opening: Mounjaro pens stable up to 21 days at <30°C; Wegovy pens stable up to 28 days at <30°C - Frozen pens must be discarded — even if thawed - Cold-chain delivery requires temperature monitoring; transit excursions outside 2–8°C invalidate the pen

Operational implication for DGP: 1. Don't hold stock in clinic. Cold-chain validation, fridge audit, and stock-loss risk are not worth the margin gain. Partner with a registered dispensing pharmacy (Pharmacy2U, Cloud Pharmacy, or a local Derby pharmacy with GPhC registration) and use a click-and-collect or post-direct-to-patient model. 2. DGP retains the prescribing relationship and clinical revenue (consultation, review, dashboard) and earns a dispensing fee or revenue share from the pharmacy partner — typically £15–£30 per prescription depending on volume. 3. This avoids £8k+ of fridge/audit/stock-loss capex and CQC scope expansion.

---

C. Prescribing Pathway — What DoctoriumGP Needs

C.1 CQC scope

Per CQC guidance on slimming clinics: a slimming clinic that prescribes weight-loss medicine carries out the regulated activity of "Treatment of disease, disorder or injury" and must be registered with CQC. DGP is already registered for this activity (per CLAUDE.md) so no scope variation is required.

Important nuance: CQC requires the regulated activity to be carried out at a registered location, i.e. a physical clinic. Pure-play online prescribers must register a physical site. DGP's Derby clinic satisfies this — even where the consultation happens by video, the regulated activity is anchored at a CQC-registered address.

C.2 Prescriber qualifications

• Dr Gemma Lewis MRCS MRCGP is a GMC-registered GP — fully entitled to prescribe Mounjaro/Wegovy in line with their licensed indications. (NHS overview of weight management injections)
• Independent prescribers (pharmacists, nurses) can also prescribe but the GP-led model is more defensible clinically and reassuring to executive buyers.
• All prescribers must be on the GMC/NMC/GPhC register with appropriate annotation.

C.3 Clinical governance documentation DGP needs in place

1. Patient screening protocol — BMI threshold (≥30, or ≥27 with weight-related comorbidity per Mounjaro SmPC), exclusion criteria (history of medullary thyroid carcinoma, MEN2, severe gastroparesis, current pregnancy / breastfeeding, severe pancreatitis history, eating disorder)
2. Consent form — documenting discussion of GI side effects, pancreatitis warning (MHRA 2026 update), discontinuation plan, weight regain risk after stopping
3. Baseline workup — bloods (HbA1c, lipids, LFTs, U&Es, TFTs), BMI, BP, weight, waist circumference. (DGP's existing Stride bloods bundle covers this neatly.)
4. Titration plan — standard 2.5 mg → 5 mg at week 4, dose-up every 4 weeks based on tolerance/response
5. Review cadence — week 4, week 12, then quarterly. Photograph weight tracker, side-effect log.
6. Yellow Card / MHRA reporting — pancreatitis, severe GI, hypoglycaemia, suicidal ideation must be reported via Yellow Card. MHRA updated 2026 guidance flags severe acute pancreatitis risk for tirzepatide.
7. Discontinuation protocol — managed taper, plan for weight maintenance (diet + exercise referral, optional dashboard tracking)

C.4 Pharmacy partnership (recommended model)

• Pharmacy2U or Cloud Pharmacy — both are GPhC-registered, offer click-to-dispatch APIs and white-label fulfilment for private clinics
• Alternative: a local Derby community pharmacy with Lilly rebate access (preferred for collection model)
• DGP issues private prescription via secure script (FP10PCD or eRx-equivalent for private)
• Patient pays DGP; DGP pays pharmacy net-of-margin; pharmacy posts cold-chain or patient collects

C.5 Patient retention realities

Real-world data (HealthVerity 2025 trends, Medscape — GLP-1 persistence) shows: - 12-month persistence has nearly doubled, from 33% (2021) to ~61% (H1 2024) for semaglutide - Patients with obesity-only have higher 12-month discontinuation (~50%) than those with diabetes (~34%) - Real-world UK private GLP-1 patient typically stays 6–18 months at £150–£300/month - ~30% drop in first 3 months (mostly nausea/cost); a further ~7% by month 12; the remaining cohort tends to stay 18+ months on maintenance

For DGP planning: - Conservative retention assumption: 60% at 12 months, 35% at 24 months - ARPU shape: rises from ~£200 (2.5–5 mg titration) to ~£280 (10 mg maintenance) over months 1–4 - Average effective monthly ARPU across 12-month cohort: ~£240

---

D. Patient Profile (UK Private GLP-1)

D.1 Headline demographics

From the Health Foundation × Voy analysis (113,630 patients, Nov 2024 – Oct 2025):

D.2 Strategic implications for DGP

1. Male share is a market gap. The whole market has trained itself on the female 30–49 menopause-adjacent buyer. DGP already has menopause depth via Gemma — but the men's longevity proposition can stake a defensible claim on the 22% male slice because no competitor is targeting it explicitly.
2. Average age 44 maps perfectly to executive longevity. The 40–55 male knowledge-worker is overweight, time-poor, has disposable income, and is increasingly health-curious (Bryan Johnson, Peter Attia, Andrew Huberman effect). GLP-1 is the most credible single intervention.
3. Less-deprived postcodes drive private spend. DGP's catchment is Derby + East Midlands + remote (online consult), so prioritising affluent postcodes (DE74, DE21, NG1, NG7, LE17, S17) is sensible.
4. GLP-1 raises testosterone in obese men by 53–77% in some studies (Pharmacy Times, Healthline) — almost entirely via reduced aromatase from fat-mass loss and improved insulin sensitivity. Powerful add-on cross-sell into TRT discussion, although DGP should avoid making this a leading marketing claim (off-licence territory; better positioned as "we measure pre/post and let the data speak").

D.3 Lifetime value (DGP modelled assumption)

No reliable UK-specific public LTV data — the search returned generic SaaS LTV templates. Modelled below.

---

E. Corporate / B2B Opportunity — GLP-1 as Executive Benefit

E.1 The size of the workplace problem

Frontier Economics 2025 update (commissioned by Nesta):

Britain's Healthiest Workplace / Vitality / RAND: - UK employees lose 49.7 days of productivity per year (2024 data); 90% of which is presenteeism - 23% of UK employees obese, 58% overweight - Obesity rate up 51% from 2014 to 2023

CIPD/Simplyhealth Health & Wellbeing at Work 2024: - Employees absent 7.8 days/year average (up from 5.8 pre-pandemic) - Public sector 10.6 days; private sector lower - Small-employer absence cost ~£547 per employee per year

E.2 What insurers cover (or don't)

Sources: Vitality enhancements launch, Bupa Weight Management Plan, Corporate Adviser — waiting for jabs, Money to the Masses — Vitality access.

E.3 The B2B opening

Most UK PMI excludes outpatient prescription drugs, including GLP-1. Vitality's discount scheme is the closest thing to a coverage option. This means employers who want to offer GLP-1 as a benefit have three routes — and DGP can serve all three:

1. Stipend / Lifestyle Spending Account model — employer reimburses up to £X/month against a private GLP-1 prescription
2. Direct contracted clinic — employer buys a block of seats on a clinical pathway (this is the DGP play)
3. Vitality top-up via their existing PMI

UK signal: Roczen, Numan and others are pivoting B2B and 20% of UK businesses now cite obesity-related conditions as the single biggest driver of rising healthcare costs. Gen Z and Millennials rank wellbeing on par with salary as a benefit.

E.4 US benchmark for ROI (informative)

Mercer 2024 employer survey, PwC, CNBC summary of CVS/employer GLP-1 study: - 44% of large US employers (500+ staff) covered weight-loss GLP-1s in 2024 (up from 41%) - 64% of employers with 20,000+ staff cover them - US GLP-1 retail $1,000–$1,500/month; employers pay 70–100%, so $700–$1,500/month per user, ~$8,400–$18,000/year - 10% utilisation among eligible employees → ~$30 PEPM ($360 PEPY) blended cost - 2-year breakeven on medical-cost reduction (CVS/Hatch study cited by CNBC) - Wellness/wellness-program literature consistently: $1 invested → $1–$3 healthcare savings, with weight-management programmes specifically returning up to $6 per $1 invested per Wellhub

Translating to UK: a £4,340–£7,165/year productivity hit per overweight/obese employee means even at £3,000–£4,000 of programme spend per employee/year, employer breakeven is plausible inside 12 months if 1 in 5 covered employees achieves >10% body-weight loss with sustained productivity gains.

---

F. ROI Calculations

F.1 Per individual patient — 12-month modelled

Assumptions (Mounjaro, base case, Lilly rebate signed):

Notes: - Without the Lilly rebate, gross medication margin compresses to £15–£30/month and net contribution is ~£300–£500. - This is conservative: bundle uplift (Tanita, GlycanAge, dashboard, Stride bloods) lifts contribution by £200–£500 per patient if 40% take it.

F.2 Per 100-patient cohort / year

This is a thin gross-margin line on its own. The case for running it = (a) acquisition wedge into the longevity bundle, (b) corporate gateway, (c) defensive positioning before the high street swallows the segment.

F.3 Corporate package — 10 key workers

Tier 1 — GLP-1 only

• 10 × £150/month × 12 = £18,000/year per company
• Cost: £14,400 medication + £2,000 clinical
• Gross contribution: ~£1,600/year
• Use case: small business CEO who just wants medication access for senior team

Tier 2 — GLP-1 + bloods + Tanita + quarterly review

• 10 × £300/month × 12 = £36,000/year per company
• Includes: medication, Stride/baseline bloods (annual + 6-mo recheck), quarterly Tanita BIA, quarterly Gemma review, dashboard portal
• Cost: £14,400 medication + £4,500 bloods + £2,000 Tanita + £6,000 clinical = £26,900
• Gross contribution: ~£9,100/year

Tier 3 — GLP-1 + full longevity bundle ("Optimise")

• 10 × £500/month × 12 = £60,000/year per company
• Includes: Tier 2 + GlycanAge biological age + VO₂ max + Nurosym (where indicated) + bespoke nutrition + monthly check-ins + executive dashboard
• Cost: ~£40,000
• Gross contribution: ~£20,000/year

Employer ROI defence (Tier 2 example): - Programme cost: £36,000 - Productivity gain: 10 employees × £4,340 (overweight) = £43,400 baseline at-risk loss; sustained 10–15% weight loss + reduced sick-day risk (1.7× → 1.0×) = ~£15,000–£20,000 productivity recovery (modelled, conservative) - PMI premium reduction: minor unless via Vitality - Talent retention proxy: 1 retention event/year saved (avg cost-of-hire ~£12,000) = £12,000 - Modelled employer breakeven: 12–18 months

(All employer-ROI figures are modelled — flagged. Frontier Economics and Britain's Healthiest Workplace data underpins the per-employee productivity loss numbers but the recovery rate is inferred.)

---

G. Risks, Side Effects, Discontinuation, Marketing Constraints

G.1 Side effect profile (tirzepatide)

From SURMOUNT-1 and meta-analyses, Mayo Clinic, Real Peptides analysis:

• GI events (nausea, diarrhoea, vomiting, constipation): dose-dependent — 39% at 5 mg, 46% at 10 mg, 49% at 15 mg
• Nausea: up to 45% on 15 mg in trials; usually resolves in 4–8 weeks
• Discontinuation due to AEs: 4.3–7.1% (5 mg) up to 25% (15 mg)
• Pancreatitis: ≤1% in trials; MHRA updated guidance 2026 flags severe acute pancreatitis risk — must be in consent
• Hypoglycaemia: rare unless co-prescribed with sulphonylureas/insulin
• Gallbladder disease, kidney injury, suicidal ideation — all listed in SmPC

G.2 Supply position

UK supply is now stable following resolution of 2024 disruption. As of Feb 2026 (WePrescribe Mounjaro update, Pharmacy Regulation update): - No active shortages on Mounjaro KwikPen - NHS rollout to 220,000 patients over 3 years is ring-fenced; private supply unaffected - Wegovy supply normalised mid-2025; new 7.2 mg dose launched Jan 2026

G.3 Off-licence prescribing risk

DGP should prescribe strictly on-licence: - Mounjaro — BMI ≥30 or ≥27 with weight-related comorbidity - Wegovy — same threshold - Avoid Ozempic and Rybelsus for weight-loss indication — both are off-licence for that purpose, increases regulatory and indemnity exposure, and is unnecessary given on-licence Mounjaro/Wegovy availability.

G.4 ASA / CAP code constraints

This is a major operational constraint. From the ASA advice on weight-control POMs, ASA enforcement notice on weight-loss POM ads, and Feb 2026 rulings against Voy/Zava/MedExpress/UK Meds Direct/Juniper:

Banned in B2C advertising: - Naming Mounjaro / Wegovy / Ozempic / Saxenda / semaglutide / tirzepatide - Using "GLP-1", "skinny jab", "weight-loss injection", "weight-loss pen" - Showing injection pens or vials - Time-limited offers, urgency language ("run, don't walk", "Black Friday") - Before/after photographs - Celebrity / HCP endorsements - Specific weight-loss claims - Influencer discount-code posts (this is what hit Voy in Feb 2026)

What DGP CAN say in marketing: - "Medical weight-management consultation" - "Comprehensive weight assessment with GP" - "Evidence-based, clinically supervised weight loss programme" - Generic mention of treatment review, not the medication - B2B / corporate communications are not subject to the same CAP restriction when sent to a defined business audience and not "advertised to the public"

Strategic implication: DGP cannot run paid Meta ads naming the medication. It can: 1. Run paid ads for "Medical weight management consultation with a GP at DoctoriumGP" with consultation-led landing pages 2. Run B2B / LinkedIn / cold email naming the products to HR buyers (B2B, not public) 3. Use SEO/content for non-naming phrases ("medical weight loss Derby", "private weight management clinic") 4. Capture demand from existing patients via the patient portal, not public ads

---

H. Strategic Positioning for DoctoriumGP

H.1 Standalone vs bundled

Recommendation: bundled into longevity tiers, with a stripped-down standalone option for entry-level patients.

Rationale: - Standalone gross margin is thin (£15–£60/month after Lilly's reset) - Bundling raises ARPU 30–80% with low marginal cost (Stride bloods, GlycanAge, Tanita all already in the DGP toolkit) - Bundles defend retention — patients stick with the platform, not the molecule - Bundles defend pricing — the patient stops comparing Numan/Voy spot-price and starts comparing programme value - A pure-medication standalone exists only to win the price-shopper at £200/month, 2.5 mg, then upsell at month 3

H.2 Pricing architecture (proposed)

H.3 Should corporate include GLP-1 by default?

Not by default — but offered as a clinically gated option in every tier. Reasons: - Not every employee in the cohort is BMI ≥27 with comorbidity; offering GLP-1 to ineligible employees is clinically and ethically wrong - Corporate package should be "Health Optimisation Programme — GLP-1 prescribed where clinically indicated, otherwise dietitian-led" - This positioning avoids the "we're selling slimming jabs to your staff" reductive framing that HR will reject

H.4 Marketing framing

• Lead message: "Performance medicine for executive men — measure, optimise, sustain."
• Position GLP-1 as one of several interventions in a clinical metabolic optimisation programme (alongside testosterone management, sleep, bloods, Nurosym, VO₂ max). Never as the headline product.
• Tone: clinical, data-led, premium. Photography of dashboards, blood markers, lab reports, body composition curves — not pens.
• Voice: Gemma's GP/MRCS/MRCGP credibility leads. "Prescribed and reviewed by a GMC-registered GP and surgeon."
• Avoid: "Skinny jab", "transformation", "summer body", any urgency language. CAP code prohibits these in B2C anyway.

H.5 Cross-sell pathway

Discovery (cold/warm)
  ↓
Free 15-min triage call
  ↓
Eligibility assessment + baseline Stride bloods (£149) ──────►   Bloods-only revenue if not eligible/declines
  ↓
Reset (medication + postage + support) £199–£349/mo
  ↓
Month 3 review → upsell to Reset+ (£49 uplift) — 60% conversion target
  ↓
Month 6 → upsell to Optimise (£399–£549) — 25% conversion target (esp. men 40+)
  ↓
Month 12 → maintenance bundle (lower medication dose or off-medication, dashboard + biomarkers) — retention play

H.6 Geographic targeting

• Catchment for in-clinic: Derby (DE) + East Midlands postcodes (NG, LE, S, B, ST). Affluent wards prioritised.
• Catchment for online consult: national. CQC scope sits at the Derby clinic location; consult by video; pharmacy posts cold-chain.
• Corporate B2B: national, but lead with East Midlands (transport, manufacturing, logistics) and London (financial services, professional services) where executive overweight is concentrated and £300–£500/month/employee budgets exist.

---

I. Investment Case — 12-month and 36-month Scenarios

All figures modelled. Key driver assumptions: Lilly rebate signed (£40/pen avg saving), avg ARPU £240/month medication, 60% 12-month retention, 35% 24-month retention, 40% bundle attach rate.

I.1 12-month base case (DGP solo, conservative)

Plus 1–2 corporate Tier 2 contracts (£36k each) = +£72k revenue, +£18k contribution.

Year 1 totals (conservative): ~£530k revenue, ~£160k gross contribution.

I.2 36-month base case

Year 3 exit run-rate: ~£2m revenue / ~£700k gross contribution from a single service line, with cross-sell into the wider Optimise / men's longevity proposition.

I.3 Stretch / upside case

If DGP wins one anchor corporate at Tier 3 (e.g. a 100-employee mid-cap covering 30 key workers at £500/month) plus four mid-size at Tier 2, Year 2 corporate alone is £600k+ revenue on top of the B2C book. Total Year 2: £1.5m+, gross contribution £450k+.

I.4 Downside case

If the Lilly rebate is not signed and DGP must price medication at break-even (£20–£30/pen margin): - B2C medication contribution shrinks to £30k/year on 80 patients - Bundle and corporate revenue still hold - Year 1: ~£90k contribution instead of £160k - Still profitable as a service line but acquisition wedge value > standalone P&L

I.5 What kills this thesis

1. NHS rollout accelerates beyond planned 220k/3yr cap → patients defect to free NHS access. Mitigants: NHS GP access remains rationed in <50% of ICBs; private patients value speed, choice, and clinician relationship.
2. Generic tirzepatide / semaglutide pre-2031 (semaglutide patent expires 2031, tirzepatide later) — collapses pricing entirely. Long-tail risk; not 36-month threat.
3. ASA tightens further (e.g. bans GP-led "consultation for weight management" landing pages). Mitigant: B2B pivot, content/SEO, existing patient base.
4. Eli Lilly withdraws rebate — compresses margins back to break-even on medication.
5. MHRA pancreatitis / serious AE signal escalates → patient enrolment cools. Manageable with consent and screening.

---

J. Recommended Next Actions (90 days)

1. Week 1–2: Sign Eli Lilly commercial rebate agreement; identify and contract a GPhC-registered dispensing pharmacy partner (Pharmacy2U, Cloud Pharmacy, or local Derby pharmacy).
2. Week 2–4: Finalise clinical SOPs (screening, consent, Yellow Card, titration, discontinuation) and patient pathway documents. Map to CQC inspection framework.
3. Week 3–5: Build the Reset / Reset+ / Optimise tiered pricing into the DGP website + Shopify + patient portal. Update menopause/men's-health landing pages with new bundles. Avoid POM names per CAP code.
4. Week 4–6: Pilot 10 male patients via existing DGP warm list (former menopause patients' partners, PT-partner referrals, Way to Wellness leads). Establish baseline data: BMI, bloods, Tanita, VO₂ max where available.
5. Week 6–10: Build B2B sales asset: "Executive Health Optimisation Programme" 1-pager + ROI calculator (using Frontier Economics figures) + sample anonymised case study. Open conversations with 5 East Midlands employers (50–250 staff) via LinkedIn + cold-email outreach.
6. Week 8–12: Finalise Vitality / Bupa / WPA gateway — DGP can accept these as PAYG referrers without being on-panel.
7. Week 12 review: Patient cohort metrics (retention, weight loss, NPS, side-effect rate) and adjust pricing / bundle composition.

---

Sources

Market sizing & demographics

• Grand View Research — UK Prescription Weight Loss Medications Market
• Lyv UK launch GlobeNewswire — 500,000 private patients
• DDW — 1.6 million UK patients used weight-loss drugs in past year
• Health Foundation × Voy: 113,630-patient analysis Nov 2024 – Oct 2025
• Healthcare Leader — GLP-1 inequalities Health Foundation
• Creo Clinic Ozempic / GLP-1 statistics
• Pulse — 1.6m UK adults on weight-loss drugs

Pricing — providers

• HeySlim — Numan Mounjaro pricing 2026
• Numan — Mounjaro programme
• Voy — Mounjaro pricing
• Voy — Mounjaro vs Wegovy comparison
• Boots Online Doctor — Mounjaro
• Boots Online Doctor — Wegovy
• Lloyds Pharmacy Online Doctor — Mounjaro
• Pharmacy2U via Bolt — Mounjaro
• Asda Online Doctor — Mounjaro
• Superdrug Online Doctor — Mounjaro
• Juniper UK — Mounjaro cost
• Juniper UK — Wegovy cost
• MyBMI — Mounjaro
• MyBMI — Wegovy prices
• Phlo Clinic Mounjaro via Bolt
• Live Well Mounjaro pen price comparison 2026
• Medino Mounjaro price comparison 2026
• Monj — Mounjaro discount price list 2026
• The Care Pharmacy — UK Mounjaro 2026 comparison
• Bolt Pharmacy — Mounjaro UK price guide
• Family Chemist — Mounjaro UK 2026

Pricing — wholesale / NHS

• NHSBSA — Mounjaro price increase Drug Tariff redetermination
• Community Pharmacy England — Mounjaro pricing for pharmacy owners
• Community Pharmacy England — Sept 2025 reimbursement redetermination
• Pharmaceutical Journal — Sept 2025 reimbursement confirmed
• Pharma Exec — Eli Lilly 170% UK price increase
• Euronews — Lilly UK price hike
• Pharmaceutical Journal — UK pharmacy stockpiling on Mounjaro
• dm+d browser — Mounjaro KwikPen 5mg AMPP

Other GLP-1s

• HeySlim — Wegovy cost UK 2026
• Voy — Wegovy 2.4 mg
• Joinvoy — Ozempic UK weight loss
• Asda Online Doctor — Ozempic for weight loss
• PrivateDoc — Saxenda cost
• London Slimming Clinic — Saxenda
• glp1treatments.co.uk — oral semaglutide UK
• Mayfair Weight Loss Clinic — Rybelsus

Regulatory / clinical

• CQC — services in slimming clinics
• NHS England — weight management injections
• House of Commons Library — weight loss medicines in England
• Mayo Clinic — Tirzepatide subcutaneous route
• PMC — tirzepatide pancreatic safety meta-analysis
• PMC — acute pancreatitis caused by tirzepatide case
• Real Peptides — tirzepatide safety review
• Pharmacy Regulation — supply concerns Mounjaro/Wegovy
• WePrescribe — Mounjaro UK supply update Feb 2026

Storage / cold chain

• Bolt Pharmacy — GLP-1 storage UK guide
• Bolt Pharmacy — GLP-1 fridge storage UK
• Novo Nordisk Medical — GLP-1 RAs storage

Patient retention / persistence

• HealthVerity — GLP-1 trends 2025
• Medscape — GLP-1 persistence has nearly doubled
• PMC — GLP-1 RA discontinuation among obesity / T2D
• PMC — discontinuation and reinitiation of dual-labelled GLP-1
• Mercer — GLP-1 discontinuation needs holistic plan

Male patients / testosterone

• Pharmacy Times — GLP-1 increases testosterone in men with obesity
• Healthline — GLP-1 drugs may improve low T
• Bolt Pharmacy — Mounjaro & testosterone interactions UK
• Game Day Men's Health — GLP-1 + TRT synergy

Insurer coverage

• Vitality enhancements launch — discounted weight loss jabs
• My Health Protected — Vitality first UK insurer to discount jabs
• Pharmacy UK — Boots & Vitality discount scheme
• Money to the Masses — accessing weight-loss drugs with Vitality
• Bupa — Weight Management Plan
• Corporate Adviser — waiting for jabs (insurer view)
• Healthcare and Protection — Vitality weight management pathway

Corporate / B2B

• Frontier Economics — Economic and productivity costs of obesity 2025
• Nesta — Economic and productivity costs of obesity report
• Frontier Economics PDF — full cost of obesity in the UK
• Vitality — Britain's Healthiest Workplace findings
• RAND Europe — Britain's Healthiest Company report
• CIPD — Health and wellbeing at work
• Verve Healthcare — UK absenteeism cost analysis 2025
• Mercer — GLP-1 considerations for 2026
• Mercer — employers enhanced health benefits 2024
• PwC — How employers can stay ahead of GLP-1 adoption
• CNBC — GLP-1s help employers lower medical costs in 2 years
• Fertifa — Lifestyle health Tier 1 employee benefit 2026
• Wellhub — Workplace wellness ROI study
• Roczen — hidden cost of obesity in workplace
• WEF — Employee health programmes obesity
• HR Dive — Mercer 44% large employers cover weight-loss drugs

Advertising / ASA

• ASA — weight control prescription-only medicines advice
• ASA — How we're trimming down problem ads for weight-loss POMs
• ASA — Updated enforcement notice on weight-loss POM ads
• Diabetes.co.uk — ASA bans weight-loss jab discount-code posts Feb 2026
• ASA ruling — Juniper Technologies UK Ltd
• ASA ruling — UK Meds Direct Ltd
• ASA ruling — Health Bridge Ltd
• ASA ruling — MedExpress Enterprises Ltd

---

End of report. ~6,200 words. UK English. All hard data sourced inline; modelled / inferred figures explicitly flagged.